Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial
Main Authors: | Minassian, AM, Silk, SE, Poulton, ID, Mitton, CH, Jin, J, Diouf, A, Querol-Rubiera, A, Bisnauthsing, K, Ogrina, T, Payne, RO, Folegatti, P, Silman, D, Batra, R, Brendish, N, Taylor, IJ, Smith, R, Berrie, E, Morelle, D, Lievens, M, Noe, AR, Soisson, LA, Ashfield, R, Long, CA, Goodman, AL, Faust, SN, Nugent, FL, Lawrie, AM, Draper, SJ |
---|---|
Format: | Conference item |
Published: |
American Society of Tropical Medicine and Hygiene
2017
|
Similar Items
-
Efficacy of the novel Plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial
by: Minassian, A, et al.
Published: (2018) -
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
by: Minassian, AM, et al.
Published: (2021) -
High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant
by: Venkatraman, N, et al.
Published: (2017) -
Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial
by: de Graaf, H, et al.
Published: (2021) -
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.
by: Payne, RO, et al.
Published: (2017)